Tag
Adjuvant pegylated interferon following nucleos(t)ide analogue withdrawal in HBeAg-negative chronic hepatitis B significantly increases HBsAg loss rates and reduces severe hepatic flares over three years compared to withdrawal alone.
This study evaluates the long-term incidence of liver cancer in chronic hepatitis B patients who clear hepatitis B surface antigen, finding significantly reduced cancer risk in younger patients without cirrhosis.
A 7-year retrospective analysis in The Gambia reveals that despite early adoption, timely Hepatitis B birth dose coverage remains critically low at 6.4%, severely hindered by weekend births and the COVID-19 pandemic.
A global systematic review (110 cohorts, 50 countries) found substantial attrition across the hepatitis B care cascade: low rates of treatment eligibility assessment and antiviral initiation in primary/community models, poor retention parti
In the phase 2 REEF‑IT trial, pegylated interferon‑α2a added to siRNA JNJ‑73763989 produced large HBsAg reductions and transient seroclearance in some untreated HBeAg‑positive patients, but no participant reached the prespecified sustained
A multinational cohort study of 1,986 patients with indeterminate chronic hepatitis B (CHB) shows large differences in long‑term hepatocellular carcinoma (HCC) risk by baseline indeterminate subtype and by phase transition, identifying subg
This review explores the potential of targeting HBx-induced HSPB1 to suppress HBV cccDNA and enhance hepatic immune responses, highlighting a promising peptide-based therapeutic approach.
Switching from nucleo(s)tide analogues to pegylated interferon alpha-2a significantly lowers virological relapse and boosts HBsAg clearance in HBeAg-negative chronic hepatitis B patients after treatment cessation.
A large multicohort study demonstrates that the China-CLIF framework outperforms existing criteria in diagnosing and predicting mortality in acute-on-chronic liver failure across all major aetiologies, with global applicability.
Explore how subtle liver symptoms can signal serious illness, the progression from hepatitis to liver cancer, and effective habits to protect your liver health.
